Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of gemcitabine and cisplatin plus Everolimus
(also called RAD001) at different dose levels. We want to find out what effects, good and/or
bad, this treatment has on you and your cancer.
Gemcitabine and cisplatin are standard chemotherapy drugs that are commonly used to treat
advanced urothelial cancer. Everolimus is a pill that works by shutting down some of the
pathways in cancer cells that make tumors grow. Laboratory studies have shown that Everolimus
appears to improve the activity of cisplatin against cancer cells.